| Alliyah Higgins-jones, OTD, OTR/L | |
|
17706 Interstate 30 N Ste 3, Benton, AR 72019-2930 | |
| (501) 315-4414 | |
| Not Available |
| Full Name | Alliyah Higgins-jones |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 17706 Interstate 30 N Ste 3, Benton, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093597379 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | OTR3858 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Alliyah Higgins-jones, OTD, OTR/L 17706 Interstate 30 N Ste 3, Benton, AR 72019-2930 Ph: () - | Alliyah Higgins-jones, OTD, OTR/L 17706 Interstate 30 N Ste 3, Benton, AR 72019-2930 Ph: (501) 315-4414 |
News Archive
Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP), a division of the European Medicines Agency (EMA), has issued an opinion recommending approval of Teysuno™ (S-1), a novel oral anti-cancer agent, intended for the treatment of advanced gastric cancer in adults when given in combination with cisplatin.
Some types of prostate tumors are more aggressive and more likely to metastasize than others. Nearly one-third of these aggressive tumors contain a small nest of especially dangerous cells known as neuroendocrine-type cells. More rarely, some aggressive prostate tumors are made up entirely of neuroendocrine-type cells. The presence of neuroendocrine-type cancer cells is associated with a poor prognosis, but spotting these rare cells can be like finding a needle in a haystack.
Gene activity in prostate cancer is reminiscent of that in the developing fetal prostate, providing further evidence that all cancers are not equal, Johns Hopkins researchers report. The finding could help scientists investigate how to manipulate the genetic program to fight a disease whose biology remains poorly understood despite more than half a century of investigation.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the "RNA Silencing: Mechanism, Biology, and Application" Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam's therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington's disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.
› Verified 7 days ago
Taralee Reeves, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1306 Military Rd Ste 1, Benton, AR 72015 Phone: 501-481-8930 | |
Mrs. Kristi Matthews, O.T. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3214 Winchester Dr., Benton, AR 72015 Phone: 501-326-6160 | |
Miss Debra Laverne Law, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1800 W Sevier, Benton, AR 72015 Phone: 501-840-5896 | |
Kimberly Michelle Jacobi, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 17706 I-30 Ste 3, Benton, AR 72019 Phone: 501-315-4414 Fax: 501-315-3467 | |
Mallory Moix, MS OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 17706 Interstate 30 N, Suite 3, Benton, AR 72019 Phone: 501-315-4414 | |
Mrs. Paula Kathryn Keys, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3214 Winchester Dr, Benton, AR 72015 Phone: 501-326-6160 Fax: 501-326-6161 |